Literature DB >> 15470047

Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia.

Melissa G Hunter1, Anand Jacob, Lynn C O'donnell, Amanda Agler, Lawrence J Druhan, K Mark Coggeshall, Belinda R Avalos.   

Abstract

Mutations in the G-CSF receptor (G-CSFR) in patients with severe congenital neutropenia (SCN) are postulated to contribute to transformation to acute myelogenous leukemia (AML). These mutations result in defective receptor internalization and sustained cellular activation, suggesting a loss of negative signaling by the G-CSFR. In this paper we investigated the roles of SHIP and cytokine-inducible Src homology 2 protein (CIS) in down-modulating G-CSFR signals and demonstrate that loss of their recruitment as a consequence of receptor mutations leads to aberrant signaling. We show that SHIP binds to phosphopeptides corresponding to Tyr744 and Tyr764 in the G-CSFR and that Tyr764 is required for in vivo phosphorylation of SHIP and the formation of SHIP/Shc complexes. Cells expressing a G-CSFR form lacking Tyr764 exhibited hypersensitivity to G-CSF and enhanced proliferation, but to a lesser degree than observed with the most common mutant G-CSFR form in patients with SCN/AML, prompting us to investigate whether suppressor of cytokine signaling proteins also down-modulate G-CSFR signals. G-CSF was found to induce the expression of CIS and of CIS bound to phosphopeptides corresponding to Tyr729 and Tyr744 of the G-CSFR. The expression of CIS was prolonged in cells with the SCN/AML mutant G-CSFR lacking Tyr729 and Tyr744, which also correlated with increased G-CSFR expression. These findings suggest that SHIP and CIS interact with distal phosphotyrosine residues in the G-CSFR to negatively regulate G-CSFR signaling by limiting proliferation and modulating surface expression of the G-CSFR, respectively. Novel therapeutic approaches targeting inhibitory pathways that limit G-CSFR signaling may have promise in the treatment of patients with SCN/AML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470047     DOI: 10.4049/jimmunol.173.8.5036

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition.

Authors:  H M Mehta; M Futami; T Glaubach; D W Lee; J R Andolina; Q Yang; Z Whichard; M Quinn; H F Lu; W M Kao; B Przychodzen; C A Sarkar; A Minella; J P Maciejewski; S J Corey
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

2.  Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis.

Authors:  Craig H Mermel; Morgan L McLemore; Fulu Liu; Shalini Pereira; Jill Woloszynek; Clifford A Lowell; Daniel C Link
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

Review 3.  Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.

Authors:  Kenneth Kaushansky
Journal:  Cytokine Growth Factor Rev       Date:  2006-10-20       Impact factor: 7.638

4.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 5.  Inhibitor and activator: dual functions for SHIP in immunity and cancer.

Authors:  William G Kerr
Journal:  Ann N Y Acad Sci       Date:  2010-12-13       Impact factor: 5.691

Review 6.  Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.

Authors:  Pankaj Dwivedi; Kenneth D Greis
Journal:  Exp Hematol       Date:  2016-10-24       Impact factor: 3.084

7.  Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival.

Authors:  Anna C Piscaglia; Thomas D Shupe; Giovanbattista Pani; Valentina Tesori; Antonio Gasbarrini; Bryon E Petersen
Journal:  J Hepatol       Date:  2009-04-05       Impact factor: 25.083

Review 8.  Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.

Authors:  Athanasia D Panopoulos; Stephanie S Watowich
Journal:  Cytokine       Date:  2008-04-08       Impact factor: 3.861

9.  Role of the proteasome in modulating native G-CSFR expression.

Authors:  Tamila L Kindwall-Keller; Lawrence J Druhan; Jing Ai; Melissa G Hunter; Pam Massullo; Megan Loveland; Belinda R Avalos
Journal:  Cytokine       Date:  2008-06-12       Impact factor: 3.861

10.  Recent advances in the bcr-abl negative chronic myeloproliferative diseases.

Authors:  Michael Bennett; David F Stroncek
Journal:  J Transl Med       Date:  2006-10-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.